Despite a diverse armamentarium of active drugs and response rates that now exceed 70%, the survival impact of chemotherapy in metastatic breast cancer is limited, and the disease remains essentially incurable (Cold et al, 1992). This frustrating, partial chemosensitivity prompted investigators to explore potential clinical applications of the relationship that had been demonstrated in laboratory models between drug dose and anti-cancer effect (Teicher et al, 1988). Random assignment trials, in which variations in dose within the 'standard' range (i.e. doses that could be administered without specialized haematopoietic support) were studied, yielded modest and inconsistent results; however the degree of dose escalation that had been attempted in these trials was relatively minor in comparison with that achieved in the laboratory (Hortobagyi et al, 1987; Bastholt et al, 1996).
Despite a diverse armamentarium of active drugs and response rates that now exceed 70%, the survival impact of chemotherapy in metastatic breast cancer is limited, and the disease remains essentially incurable (Cold et al, 1992) . This frustrating, partial chemosensitivity prompted investigators to explore potential clinical applications of the relationship that had been demonstrated in laboratory models between drug dose and anti-cancer effect (Teicher et al, 1988) . Random assignment trials, in which variations in dose within the 'standard' range (i.e. doses that could be administered without specialized haematopoietic support) were studied, yielded modest and inconsistent results; however the degree of dose escalation that had been attempted in these trials was relatively minor in comparison with that achieved in the laboratory (Hortobagyi et al, 1987; Bastholt et al, 1996) .
The development of marrow autografting facilitated the study of very high doses of some drugs, prominently the alkylating agents, and allowed clinical investigators to mimic the levels of drug exposure that had been assayed in the preclinical systems. The first trials of high-dose chemotherapy with autograft support in breast cancer were performed in patients with disease that had failed conventional treatment. While high rates of response were achieved, indicating that dose escalation could indeed partly overcome drug resistance, these responses were of brief duration. In addition treatment-related mortality occurred in up to 20% of patients (Eder et al, 1986) . In subsequent studies in patients without prior chemotherapy for metastases, approximately 50% achieved remission and, provocatively, a minority of these remained durable (Peters et al, 1988; Ghallie et al, 1994) .
Investigators next turned to a strategy based on an interpretation of the work of Norton and Simon (1986) . According to their kinetic model, cancer cells grew and regressed -not in the strictly exponential fashion that had previously been proposed (Skipper and Schabel, 1982) but in a Gompertzian manner. The essential feature of Gompertzian kinetics is that the growth fraction of the tumour is not constant, as would be predicted by the exponential model, but rather varies with the size of the tumour. As tumours grow larger, their growth rate decreases. They further hypothesized that the rate of regression of a cancer was related to the dose of chemotherapy administered and to the growth rate of the unperturbed tumour at that phase of its growth curve. Thus, small tumours should be relatively more sensitive to chemotherapy than large ones. Paradoxically, the very high growth rate of very small, subclinical tumours makes their eradication difficult to achieve. Thus, according to Norton and Simon (1986) , a phase of 'late intensification' of therapy would be necessary to eradicate a tumour that had been cytoreduced by prior conventional chemotherapy. In the 1970s and 1980s, many groups had studied this approach (using doses substantially less intensive than those achieved with autografting) in patients with different cancers. While some of these trials were positive, the benefit was generally modest (Perloff et al, 1996) . The fact that this strategy did not have a greater curative impact might indicate that the level of late intensification achieved in these studies was insufficiently high to have a meaningful impact on drug resistance. Thus, autografting, which facilitated substantial dose-escalation, and the Norton-Simon model seemed to be made for one other. A further theoretical advantage of the ,standard-dose induction' -'high-dose consolidation' approach was that it identified patients with resistant disease who were known not to benefit substantially from high-dose therapy.
This strategy became the dominant model, and it produced relatively consistent results. Overall and complete response rates were approximately 80-90% and 50-70% respectively. Most of these remissions still ended in relapse, however, and the results were not convincingly superior to those that had been reported for high-dose chemotherapy without prior induction. Nevertheless, the occurrence of durable remissions in 10-20% of patients suggested the possibility that this might be a curative treatment for a minority of patients with metastatic disease (Kennedy et al, 1991; Antman et al, 1992; Crown et al, 1995) There was, of course, a substantial potential for selection bias in these single-arm studies, and there was general acceptance of the need for prospective randomized trials (Henderson, 1990) . However, even if these results were to be confirmed, high-dose therapy would remain a poor treatment for metastatic disease, with only a small minority of patients achieving durable remissions. With the decline in treatment-related mortality that occurred following the introduction of peripheral blood progenitors, (Gianni et al, 1989; Brugger et al, 1993; Peters et al, 1993a) relapse from complete remission had in fact emerged as the leading cause of failure.
An interpretation of these results based on the Goldie-Coldman model would suggest that these relapses were inevitably due to the persistence, or emergence, of diverse clones of cancer cells with varying drug resistance mechanisms (Goldie and Coldman, 1979) . In an attempt to overcome this problem, Gianni et al (1992) devised innovative regimens which sequentially delivered high doses of different single agents that were putatively susceptible to different drug-resistance mechanisms (Patrone et al, 1995) . Both the 'induction-consolidation' and the 'high-dose sequential models' are, however, based on the premise that populations of cells that are sensitive to a treatment can be efficiently eradicated by a single application of that treatment -a hypothesis which is not entirely consistent with classical chemotherapy theory and practice . The cure of Hodgkin's disease (DeVita et al, 1970) and testis cancer (Einhom et al, 1977) resulted from the identification of highly active regimens and the application of a sufficient number of cycles of those regimens to eradicate the cancer. As the high-dose programmes used with stem-cell support appear to be the most active regimens that are currently available for the treatment of metastatic breast cancer, would it not be logical to treat patients with multiple cycles of these highly active regimens rather than prefacing their use with treatments that, in the context of cure, are highly ineffective?
This approach might in fact be more consistent with the Norton-Simon model, the ultimate logic of which is that all treatment courses should be given in high dose. Furthermore, the observation that Gompertzian kinetics predicted rapid regrowth of small volume residual tumours argues for abbreviated treatment intervals. In the 1970s (when this hypothesis was first advanced), haematopoietic support technology was rudimentary, and a single cycle of high-dose therapy was as much as most, but not all, (Dunphy and Spitzer, 1992) investigators attempted. Thus induction -consolidation was the most feasible adaptation of the model at that point in time. The introduction of peripheral blood progenitors subsequently facilitated the investigation of multi-cycle highdose therapy at either standard or accelerated treatment intervals. This strategy is now under investigation (Crown et al, 1992 (Crown et al, , 1993 (Crown et al, , 1994 Ayash et al, 1994; Fennelly et al, 1995 Rodenhuis et al, 1996) . It is against this historical and theoretical backdrop that we should consider the results of the first two randomized studies of high-dose chemotherapy in metastatic breast cancer.
Bezwoda et al (1995) randomly assigned patients with chemotherapy-naive metastatic disease to receive either conventionallydosed mitoxantrone, vincristine and cyclophosphamide or high-doses of cyclophosphamide, etoposide and mitoxantrone without induction therapy. The high-dose treatment produced significantly superior response and survival. The study was relatively small, and a disproportionate number of patients on the high-dose arm received tamoxifen post chemotherapy. In addition, patients on the low-dose arm had rather poor survival. It is, however, interesting to note that many of the patients on the highdose arm were not hospitalized for complications of cytopenia, a finding which suggests that this high-dose regimen was less intensive that those that had been used in other studies.
The second study (Peters et al, 1996) was a test of the classic induction -high-dose consolidation model. Patients with metastatic breast cancer who had achieved a complete response to conventional chemotherapy were randomized to undergo highdose therapy as immediate consolidation or to receive no further treatment until they relapsed; 'salvage' high-dose chemotherapy was then applied. The cohort who underwent consolidation had a highly significantly prolonged disease-free survival compared with those who were transplanted at relapse, supporting the concept of 'late-intensification'. Paradoxically, the latter group of patients had superior overall survival. While this apparently confusing observation requires explanation and confirmation, high-dose chemotherapy was, again, associated with 5-year survival in a proportion of patients, including non-randomized patients who were transplanted in partial response. A further implication of these results is that a reconsideration of this therapy in relapsed metastatic disease may be required.
It may be that these two trials taken collectively show us that high-dose therapy is indeed more active than low-dose therapy, but that the induction -consolidation model might not represent its most efficient use. While these studies partly establish the credibility of high-dose therapy, conventionally dosed chemotherapy has also improved in recent years, and it is essential that the conventional arms of future confirmatory trials should also be optimized. In one such initiative, the European Breast Cancer Dose-Intensity Study (EBDIS), patients receive docetaxel and anthracycline followed by either cyclophosphamide methotrexate 5-fluorouracil (CMF) or two autograft-supported high-dose cycles. In future studies, investigators will likely address the relative merits of the different high-use strategies and the potential impact of graft engineering (Shpall et al, 1994; Brugger et al, 1995) . The impact of high-dose chemotherapy may also be greater in the setting of high-risk stage II-III disease in which the tumour burden is much smaller than it is in patients with clinically overt metastases. Promising results have been reported from single-arm studies (Gianni et al, 1992; Peters et al, 1993b) , and this approach is now the subject of large international randomized trials.
The last year has been an exciting one for students of high-dose therapy. We may be justified in believing that the first randomized trials have brought us to the 'end of the beginning'. Hopefully, current studies may herald the 'beginning of the end'. 
